Ephrb4-Ephrinb2 signaling was correlated with angiogenesis, tumor progression and anti-angiogenic drug resistance (Noren et al., 2004; Krusche et al., 2016; Uhl et al., 2018). The gene discussed is EFNB2; the disease is neoplasm.